ArticleFrontiers in psychiatry2025
Factorial invariance of the generalized anxiety disorder scale (GAD-7) in Latin America and the Caribbean.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Factorial invariance of the Spanish version of the PHQ-9 by gender and country in Latin America and the Caribbean.Frontiers in psychiatry · 2025Article
- Reliability and convergent validity of the PHQ-2 for the rapid detection of depressive symptoms in healthcare professionals in Argentina.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The prevalence of Generalized Anxiety Disorder (GAD) has increased rapidly, highlighting the importance of its detection using quick tools applicable to men and women from different countries. Objective: To analyze the psychometric properties of the Generalized Anxiety Disorder Test (GAD-7) by gender and country in Latin America and the Caribbean (LAC). Method: A cross-sectional e-health study with 12,124 participants from 15 LAC countries (54.32% women, 45.68% men) was conducted, including participants from Argentina (7.3%), Bolivia (6.7%), Colombia (10.3%), Chile (6.9%), Costa Rica (4.9%), El Salvador (5.7%), Ecuador (7.2%), Guatemala (4.7%), Panama (5.1%), Paraguay (5.7%), Peru (8.6%), Puerto Rico (5.8%), the Dominican Republic (6.6%), Uruguay (6.3%), and Venezuela (8.2%). All participants completed the GAD-7 scale digitally. Results: A unidimensional structure of the GAD-7 was confirmed, explaining 70% of the variance. The model fit indices were adequate (RMSEA = 0.062; CFI = 0.997; TLI = 0.995; SRMR = 0.017; p < 0.001), and the factor loadings for each item were satisfactory (> 0.70). Additionally, the factor structure showed measurement invariance between genders and countries, with adequate fit indices at all levels (configural, metric, scalar, and strict), suggesting that the measurements are equivalent in both contexts. Finally, the internal consistency of the GAD-7 was high, with a McDonald's Omega coefficient of 0.91. Conclusions: The GAD-7 exhibits a factor structure that is equivalent across genders and countries, demonstrating its validity and reliability for the rapid detection of GAD symptoms in different countries within the region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.